These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11132226)

  • 1. Report of severe neurotoxicity with cyclophosphamide.
    Nagarajan R; Peters C; Orchard P; Rydholm N
    J Pediatr Hematol Oncol; 2000; 22(6):544-6. PubMed ID: 11132226
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone marrow transplantation for Fanconi anemia. Adjustment of the dose of cyclophosphamide for preconditioning.
    Yabe M; Yabe H; Matsuda M; Hinohara T; Oh Y; Hattori K; Ishikawa K; Ohshima T; Yamamoto H; Kato S
    Am J Pediatr Hematol Oncol; 1993 Nov; 15(4):377-82. PubMed ID: 8214359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
    Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
    Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditioning regimens for marrow grafting.
    van Bekkum DW
    Semin Hematol; 1984 Apr; 21(2):81-90. PubMed ID: 6377501
    [No Abstract]   [Full Text] [Related]  

  • 5. Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning.
    Medeiros C; Zanis-Neto J; Pasquini R
    Bone Marrow Transplant; 1999 Oct; 24(8):849-52. PubMed ID: 10516695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation from matched siblings in patients with fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin.
    Ayas M; Solh H; Mustafa MM; Al-Mahr M; Al-Fawaz I; Al-Jefri A; Shalaby L; Al-Nasser A; Al-Sedairy R
    Bone Marrow Transplant; 2001 Jan; 27(2):139-43. PubMed ID: 11281382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late graft rejection following allogeneic bone marrow transplantation in aplastic anemia.
    Rodriguez V; Khan SP
    Transplant Proc; 2002 Jun; 34(4):1307-9. PubMed ID: 12072347
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.
    Maschan AA; Kryzanovskii OI; Yourlova MI; Skorobogatova EV; Pashanov ED; Potapova YE; Timonova LA; Bogatcheva NY; Samochatova EV; Roumjantzev AG
    Bone Marrow Transplant; 1997 Feb; 19(4):385-7. PubMed ID: 9051250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
    Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
    Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.
    Stepensky P; Shapira MY; Balashov D; Trakhtman P; Skorobogatova E; Rheingold L; Brooks R; Revel-Vilk S; Weintraub M; Stein J; Maschan A; Or R; Resnick IB
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1282-8. PubMed ID: 21220033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppression for clinical marrow transplantation.
    Santos GW
    Semin Hematol; 1974 Jul; 11(3):341-51. PubMed ID: 4151847
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of aplastic anaemia: first do no harm.
    Marsh JC
    Lancet; 2000 Nov; 356(9241):1536-7. PubMed ID: 11075760
    [No Abstract]   [Full Text] [Related]  

  • 13. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation.
    Gluckman E; Devergie A; Dutreix J
    Br J Haematol; 1983 Jul; 54(3):431-40. PubMed ID: 6344915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of aplastic anemia].
    Kleihauer E
    Monatsschr Kinderheilkd; 1988 Dec; 136(12):772-8. PubMed ID: 3070360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unrelated bone marrow transplantation in two severe aplastic anemia patients preconditioned with a regimen of cyclophosphamide, antithymocyte globulin, and total body irradiation].
    Mizue N; Watanabe J; Katoh S; Oda T; Suzuki N; Kudoh T
    Rinsho Ketsueki; 1999 Mar; 40(3):213-7. PubMed ID: 10222628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia.
    Thakar MS; Bonfim C; Walters MC; Storb R; Pasquini R; Burroughs L; Sandmaier BM; Woolfrey A; Kiem HP
    Bone Marrow Transplant; 2017 Apr; 52(4):570-573. PubMed ID: 28067886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cyclophosphamide in aplastic anaemia.
    Brodsky RA; Jones RJ
    Lancet; 2001 Apr; 357(9262):1128-9. PubMed ID: 11303606
    [No Abstract]   [Full Text] [Related]  

  • 19. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
    Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of schedule of administration of adjunctive, short-term immunosuppression in ALS- and bone marrow cell-treated, skin-allografted mice.
    Gozzo JJ; Plowey J; Hartner WC; De Fazio SR
    Transplant Proc; 1995 Feb; 27(1):169-70. PubMed ID: 7878958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.